




Clariss Biotech I Fund



We believe we can generate **outstanding returns** and give hope to patients from all around the world by partnering with top research centers and pharmaceutical leaders to turn **science** into **cure**

Clariss Biotech I: €85m fund to be rapidly invested in 10-12 companies

Fund size: €85m

- Final closing led by European Investment Fund and CDP Venture Capital

Target portfolio

- 10-12 investments

We devote our attention to high-potential projects at pre-clinical or Phase I stage...



- Leads with a clear target and positive pre-clinical data
- Targeting indications with no effective cure, mainly in oncology, rare diseases and other high need areas;
- From pre-clinical to Phase I
- **Clinical proof of concept in 3-4 years** from investment (Phase I or Phase IIa/IIb evidence), with **high-price reimbursement** perspective and **compelling target product profile**

What we are looking for

Trigger	Details
Highly unmet clinical need	<ul style="list-style-type: none">• Severity of the disease• Safety/Efficacy of available therapies• Competitive compounds in clinical development
Compelling reimbursement case (based on target product profile)	<ul style="list-style-type: none">• Transformational vs. incremental improvement• Pricing scenarios• Target population• Target product profile
Preclinical proof of concept	<ul style="list-style-type: none">• Scientific evidence in vitro/in vivo
Robust IP	<ul style="list-style-type: none">• Protection (strength and duration)• Freedom to operate
Pipeline / Platform opportunities	<ul style="list-style-type: none">• Other compounds under development• Opportunity to apply same biotechnology/approach to develop other compounds

Hands on approach

Areas of contribution	Support provided by Claris Ventures
Strategic Positioning	<ul style="list-style-type: none">• Identification of high potential product positioning options, based on scientific and market input
Development Plan	<ul style="list-style-type: none">• Definition, validation and setup of development activities
Financial Controlling	<ul style="list-style-type: none">• Setup of key budgeting and controlling routines
Team (executive)	<ul style="list-style-type: none">• Recruitment of key managers• Coaching of scientific founders
Team (non-executive)	<ul style="list-style-type: none">• Attraction of BoD members or senior advisors
Business Development and exit	<ul style="list-style-type: none">• Early match making with possible co-investors (follow-ons), buyers (path to exit) or synergistic companies (pipeline strengthening or co-development)

Who we are

Claris Ventures Investment Team



Pietro Puglisi (Partner): 10-year VC experience, previous experience as management consultant in pharma&biotech industry; biomedical engineering background, MBA.



Ciro Spedaliere (Partner): 12-year VC experience, previous experience as product and marketing manager; management engineering background; Venture Capital Executive Program at Haas, Berkeley.



Francesco Fontana (Analyst): 2-year experience in multinational companies; degree in engineering, MBA and PhD in entrepreneurial finance.

Venture Partner



Fabio D'Agostino: 10-year experience as life science consultant; biomedical engineering background, PhD in biopharmaceutical process development.

Investment Committee



Laura Iris Ferro: former CEO and founder at Gentium, Nasdaq listed pharmaceutical company acquired by Jazz Pharmaceuticals for \$1bn in 2014.



Manilo Marocco: experienced investment banking professional (Salomon Brothers, SpringWater Capital, Stirling Square Capital Partners), currently CEO at SocialFare Seed fund and Board Member at Tiscali.



Roberto De Ponti: Head of Corporate New Ventures and Strategic Investments at Helsin pharmaceutical group.



Pietro Puglisi

pietro.puglisi@clarisventures.com

Ciro Spedalieri

ciro.spedalieri@clarisventures.com

Office: via Santa Giulia 1, Turin (Italy)